IBRX
ImmunityBio Inc

19,129
Loading...
Loading...
News
all
press releases
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals
The stock’s recent momentum has been fueled by fresh optimism around trial data for its cancer drug Anktiva, which showed survival benefits in resistant lung cancer patients.
Stocktwits·17d ago
News Placeholder
More News
News Placeholder
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
Meme mania has resurged in the past few months.
Stocktwits·22d ago
News Placeholder
ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
Zacks·4mo ago
News Placeholder
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside
Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.
Stocktwits·5mo ago
News Placeholder
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
Zacks·5mo ago
News Placeholder
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive
ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).
Stocktwits·5mo ago
News Placeholder
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.
Stocktwits·8mo ago
News Placeholder
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital...
Business Wire·8mo ago
News Placeholder
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing...
Business Wire·8mo ago

Latest IBRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.